Celon Pharma S.A. at the American Diabetes Association’s 78th Scientific Sessions

On 24 June 2018, representatives of Celon Pharma’s Metabolic Disorders Research Group will take part in a poster session, during which they will make a presentation on the following subject: Discovery of CPL207-280ca, an effective and safe GPR40 agonist for the treatment of type 2 diabetes.

The conference is the world's largest event bringing together researchers, health professionals and companies specialising in topics related to diabetes treatment and patient education in this therapeutic area.